Early-stage returns?
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 17093473.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Contrary to conventional thinking, there are compelling reasons for investors to consider early-stage life science ventures, especially in the context of a maturing biotech business 'ecosystem'.
Medical subject headings
- Biotechnology
- Capital Financing
- Drug Industry
- Investments